Comparative Efficacy and Safety of Front-line Regimens for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Network Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-958; Location: LEVEL 3, HALL B3; " We searched PubMed, Embase, and 2024–2026 conference abstracts for prospective trials of frontline TKIs (imatinib, dasatinib, ponatinib) with chemotherapy or blinatumomab. Ponatinib plus blinatumomab is the most effective front-line regimen for Ph–positive ALL, offering superior molecular depth and survival. These findings support chemotherapyfree protocols as the new standard of care and suggest that deep molecular responses may safely allow the omission of front-line SCT. CMR: complete molecular response, CrI: credible interval, EFS: event-free survival, HR: hazard ratio, hyper-CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, MRD: measurable residual disease, OS: overall survival, SCT: stem cell transplant, SUCRA: surface under the cumulative ranking curve."
Retrospective data • Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Kotesh Korra 1; Labannya Das Puja 2; Yashas Maragowdanahalli Somegowda 3; Akash Rawat 4; Oriona Vinishia 5; Harshawardhan Dhanraj Ramteke 6; Sourav Hazra 7; Rakhshanda Khan 8
|